Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Con Dolianitis

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The Journal of Dermatology|June 25, 2019
Topical dapsone gel for treatment of axillary subcorneal pustular dermatosisBrent J Doolan, William C Cranwell, Jenny Nicolopoulos, et al.
The Australasian Journal of Dermatology|February 23, 2019
Pseudolymphoma induced by secukinumab for treatment of chronic plaque psoriasisWilliam C Cranwell, Brent J Doolan, Barbara Radulski, et al.
The Australasian Journal of Dermatology|July 7, 2020
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativaYonatan Kok, Jenny Nicolopoulos, Anne Howard, et al.
The Australasian Journal of Dermatology|February 18, 2020
Measuring treatment response to adalimumab in hidradenitis suppurativa patients: An observational studyYonatan Kok, Jenny Nicolopoulos, Anna Braue, et al.
The Journal of Dermatological Treatment|May 11, 2017
Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis populationDiana Norris, Louise Photiou, Mark Tacey, et al.
The Australasian Journal of Dermatology|July 9, 2022
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)Peter Foley, Nick Manuelpillai, Con Dolianitis, et al.
The Australasian Journal of Dermatology|September 5, 2020
Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis RegistryBrent J Doolan, Digsu Koye, Joanna Ling, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The Journal of Dermatology|June 25, 2019
Topical dapsone gel for treatment of axillary subcorneal pustular dermatosisBrent J Doolan, William C Cranwell, Jenny Nicolopoulos, et al.
The Australasian Journal of Dermatology|February 23, 2019
Pseudolymphoma induced by secukinumab for treatment of chronic plaque psoriasisWilliam C Cranwell, Brent J Doolan, Barbara Radulski, et al.
The Australasian Journal of Dermatology|July 7, 2020
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativaYonatan Kok, Jenny Nicolopoulos, Anne Howard, et al.
The Australasian Journal of Dermatology|February 18, 2020
Measuring treatment response to adalimumab in hidradenitis suppurativa patients: An observational studyYonatan Kok, Jenny Nicolopoulos, Anna Braue, et al.
The Journal of Dermatological Treatment|May 11, 2017
Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis populationDiana Norris, Louise Photiou, Mark Tacey, et al.
The Australasian Journal of Dermatology|July 9, 2022
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)Peter Foley, Nick Manuelpillai, Con Dolianitis, et al.
The Australasian Journal of Dermatology|September 5, 2020
Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis RegistryBrent J Doolan, Digsu Koye, Joanna Ling, et al.
Pageof 3